RG-6080

• CAS: 1452458-86-4
• Catalog Number: ACM1452458864
• Category: Inhibitors
• Molecular Weight: 324.31
• Molecular Formula: C9H16N4O7S
• Description: Nacubactam, also known as RG-6080, FPI-1459, and OP-0595, is a beta-lactamase inhibitor used for treating bacterial infections.
• Synonyms: RG-6080; RG 6080; RG6080; FPI-1459; FPI 1459; FPI1459; OP-0595; OP 0595; OP0595; Nacubactam
• IUPAC Name: (1R,2S,5R)-2-((2-aminoethoxy)carbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate
• Canonical SMILES: O=S(O)(ON1[C@]2([H])CC[C@@H](C(NOCCN)=O)[N@@](C2)C1=O)=O
• InChI: InChI=1S/C9H16N4O7S/c10-3-4-19-11-8(14)7-2-1-6-5-12(7)9(15)13(6)20-21(16,17)18/h6-7H,1-5,10H2,(H,11,14)(H,16,17,18)/t6-,7+/m1/s1
• InChI Key: RSBPYSTVZQAADE-RQJHMYQMSA-N
• Solubility: Soluble in DMSO and water
• Appearance: Off-white to beige solid powder
• Shelf Life: >2 years if stored properly
• Storage: Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
• Alternative CAS: 2007923-17-1 (hydrate); 1452458-86-4 (free acid)
• Biological Target: Nacubactam (OP0595 free acid) is a potent non-β-lactam-β-lactamase inhibitor with activity against class A and class C β-lactamases.
• Drug Formulation: This drug may be formulated in DMSO
• Elemental Analysis: C, 33.33; H, 4.97; N, 17.28; O, 34.53; S, 9.89
• Exact Mass: 324.074
• HS Tariff Code: 2934.99.9001
• In Vitro Activity: To assess the functional concentration of OP0595 for use with β-lactam agents, the MICs (the lowest concentration to prevent visible growth after incubation at 35°C for 18 to 20 h) of piperacillin, cefepime, and meropenem in combination with different concentrations of OP0595 were determined against five strains of CTX-M-15-positive E. coli and five strains of KPC-positive K. pneumoniae. The log averages of MICs were plotted as the geometric mean MICs (Fig. 1). For all β-lactam agents, the geometric mean MICs decreased as the OP0595 concentrations increased, regardless of the type of partner β-lactam agent or the bacterial species. In each case, the MIC reached a plateau at 2 to 4 μg/ml of OP0595. These results suggest that a concentration of 4 μg/ml of OP0595 against these strains is sufficient to result in maximal MIC reduction in in vitro studies.; Reference: Antimicrob Agents Chemother. 2016 Apr 22;60(5):3001-6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862534/
• In Vivo Activity: A neutropenic murine model of thigh infection was used to clarify the efficacy of OP0595 alone and in combination with cefepime in vivo. The strains tested were CTX-M-15-positive E. coli MSC20653 and MSC20662 and KPC-positive K. pneumoniae ATCC BAA-1705 and ATCC BAA-1904, which have been confirmed to grow in the thigh of neutropenic Crlj:CD1 (ICR) mice. The viable cell counts of CTX-M-15-positive E. coli MSC20653 or MSC20662 in control mice and in mice after administration of the test compounds are shown in Fig. 3A. The viable cell count in mice treated with cefepime (10 mg/kg) or OP0595 (2.5 mg/kg) was not significantly lower than that in mice treated with vehicle at 23 h after the start of treatment. However, mice in the cefepime-OP0595 groups (5/1.25 mg/kg and 10/2.5 mg/kg) had significantly (P < 0.05) lower bacterial counts than those in the saline vehicle group. Cefepime-OP0595 showed stronger efficacy than cefepime alone against all β-lactamase-positive strains tested, whereas OP0595 alone showed weaker or no efficacy. Taken together, these data indicate that combinational use of OP0595 and a β-lactam agent is important to exert the antimicrobial functions of OP0595.; Reference: Antimicrob Agents Chemother. 2016 Apr 22;60(5):3001-6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862534/
• Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
• Stock Solution Storage: 0-4 °C for short term (days to weeks), or -20 °C for long term (months).